|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study aimed to confirm the association of the transmembrane 6 superfamily member 2 (TM6SF2) E167K variant with non-alcoholic fatty liver disease (NAFLD) and the degree of steatosis, as well as the additive effect of body mass index (BMI) or the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M and TM6SF2 E167K variants in NAFLD.
|
31054977 |
2020 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PRO-C3 concentration appears to be linked to both fibrosis and steatosis and increased in carriers of the TM6SF2 rs58542926 risk allele.
|
30859582 |
2019 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This patient exhibited liver steatosis; he was neither diabetic, nor obese or alcoholic, but is a carrier of 2 polymorphisms, p.Ile148Met (rs738409) and p.Glu167Lys (rs58542926) on PNPLA3 and TM6SF2 gene, respectively, previously shown to be associated with nonalcoholic steatosis and fibrosis evolution.
|
28711549 |
2018 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This patient exhibited liver steatosis; he was neither diabetic, nor obese or alcoholic, but is a carrier of 2 polymorphisms, p.Ile148Met (rs738409) and p.Glu167Lys (rs58542926) on PNPLA3 and TM6SF2 gene, respectively, previously shown to be associated with nonalcoholic steatosis and fibrosis evolution.
|
28711549 |
2018 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
PNPLA3 rs738409, GCKR rs780094 and TM6SF2 rs58542926 variants were independent risk factors of hepatic steatosis and elevated ALT levels.
|
29314568 |
2018 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Metabolic effects of LYPLAL1 rs12137855-C were similar, but statistically less robust, to the effects of GCKR rs1260326-T. TM6SF2 rs58542926-T displayed opposite metabolic effects when compared with the fatty liver associations.
|
29648650 |
2018 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, the TM6SF2 E167K variant promotes the development of steatosis, fibrosis and cirrhosis in patients with chronic hepatitis C. Conversely, this variant reduces circulating atherogenic lipid fractions.
|
28839198 |
2017 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The associations between the rs738409 PNPLA3 gene polymorphism and steatosis and advanced fibrosis were tested under a recessive inheritance model using logistic regression analysis, including age, gender, BMI, ethnicity/color, HOMA-IR, alcohol intake, HCV genotype 3, and the rs58542926 TM6SF2 gene polymorphism as covariates.
|
29258449 |
2017 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, the low-frequency E167K variant of TM6SF2 and rare mutations in APOB, which impair very low-density lipoproteins secretion, predispose to progressive fatty liver.
|
26409295 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Reduction of Caloric Intake Might Override the Prosteatotic Effects of the PNPLA3 p.I148M and TM6SF2 p.E167K Variants in Patients with Fatty Liver: Ultrasound-Based Prospective Study.
|
26745555 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Glu167Lys (E167K) transmembrane 6 superfamily member 2 (TM6SF2) variant has been associated with liver steatosis, high alanine transaminase (ALT) levels and reduced plasma levels of liver-derived triglyceride-rich lipoproteins.
|
25893821 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
After adjustment for age, gender, body mass index and homoeostasis model assessment score, steatosis severity was independently associated with IL28B rs12979860 (odds ratio [OR] 0.69, 95% confidence interval [CI] 0.55-0.86, P = 0.001) and PNPLA3 rs738409 (OR 1.84, 95% CI 1.46-2.83, P < 0.001), but not TM6SF2 rs58542926 (OR 1.48, 95% CI 0.82-2.69, P = 0.19).
|
26259026 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The TM6SF2 E167K substitution promotes steatosis and lipid abnormalities in part by altering TM6SF2 and microsomal triglyceride transfer protein expression and differentially impacts CHC and chronic hepatitis B viral load, while effects on fibrosis are marginal.(Hepatology 2016;64:34-46).
|
26822232 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In HIV/HCV coinfection the TM6SF2 E167K variant is an independent predictor of severe fibrosis, but appears to be independently associated with severe steatosis only for patients with a non-3 HCV genotype.
|
27784963 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Associations of the single nucleotide polymorphisms (SNP) PNPLA3 rs738409 and TM6SF2 rs58542926 with hepatic steatosis have recently been established.
|
26847197 |
2016 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In 100 treated patients matched 1:1 for modality of recruitment, gender, presence of IFG or type 2 diabetes, PNPLA3 I148M risk alleles, TM6SF2 E167K variant, age, and BMI, statin use remained associated with protection from steatosis (OR 0.09, 95% C.I.
|
25980762 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This is the first demonstration that TM6SF2 E167K variant is an independent predictor of liver steatosis in chronic hepatitis C.
|
25581573 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
TM6SF2 E167K variant impacts on steatosis severity and is associated with liver damage and fibrosis in patients with CHC.
|
25820484 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Carriers of the TM6SF2 E167K variant have fatty liver as a result of reduced secretion of very-low-density lipoproteins (VLDLs).
|
25251399 |
2015 |
|
rs58542926
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A discrete trait analysis of NAFLD showed that rs58542926 was associated with a modest risk of fatty liver (P = 0.038; odds ratio [OR]: 1.37; 95% confidence interval [CI]: 1.02-1.84); nevertheless, conditioning on patatin-like phospholipase domain-containing 3 (PNPLA3)-rs738409 abolished this effect.
|
25302781 |
2015 |